

1. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *Lancet Oncol* 2012;13(6):607–615.
2. Schiller JT, Lowy DR. Virus infection and human cancer: an overview. *Recent Results Cancer Res* 2014;193:1–10.
3. Chen CJ, Hsu WL, Yang HI, et al. Epidemiology of virus infection and human cancer. *Recent Results Cancer Res* 2014;193:11–32.
4. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. *Cell* 2009;138(1):30–50.
5. Campo MS, O'Neil BW, Barron RJ, et al. Experimental reproduction of the papilloma-carcinoma complex of the alimentary canal in cattle. *Carcinogenesis* 1994;15(8):1597–1601.
6. Khoury JD, Tannir NM, Williams MD, et al. Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. *J Virol* 2013;87(16):8916–8926.
7. zur Hausen H, de Villiers EM. TT viruses: oncogenic or tumor-suppressive properties? *Curr Top Microbiol Immunol* 2009;331:109–116.
8. Mizutani T, Sayama Y, Nakanishi A, et al. Novel DNA virus isolated from samples showing endothelial cell necrosis in the Japanese eel, *Anguilla japonica*. *Virology* 2011;412(1):179–187.
9. Paulson KC, Carter JJ, Johnson LG, et al. Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. *Cancer Res* 2010;70:8388–8397.
10. International Agency for Research on Cancer (IARC) Working Group. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Malaria and Some Polyomaviruses (SV40, BK, JC, and Merkel Cell Viruses)*, Vol. 104. Lyon, France: IARC; 2013.
11. Moore PS, Chang Y. The conundrum of causality in tumor virology: the cases of KSHV and MCV. *Semin Cancer Biol* 2013;26C:4–12.
12. Rigoni-Stern D. Fatti statistici relativi alle malattie cancerose. *Giornale Service Progr Pathol Therap Ser* 1842;2:507–517.
13. Lowy DR. History of papillomavirus research. In: Garcea RL, DiMaio D, eds. *The Papillomaviruses*. New York, NY: Springer; 2007:13–28.
14. zur Hausen H. Herpes simplex virus in human genital cancer. *Int Rev Exp Pathol* 1983;25:307–326.
15. Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. *Proc Natl Acad Sci U S A* 1983;80(12):3812–3815.
16. Boshart M, Gissmann L, Ikenberg H, et al. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. *Embo J* 1984;3(5):1151–1157.
17. Christensen ND. Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies. *Antivir Chem Chemother* 2005;16(6):355–362.
18. Rous P, Beard J. The progression to carcinoma of virus induced rabbit papillomas (Shope). *J Exp Med* 1935;62:523–545.
19. Syverton JT, Berry GP. Carcinoma in the cottontail rabbit following spontaneous virus papilloma (Shope). *Proc Soc Exp Biol Med* 1935;33:399–400.
20. de Villiers EM. Cross-roads in the classification of papillomaviruses. *Virology* 2013;445(1–2):2–10.
21. Bosch FX, Broker TR, Forman D, et al. Comprehensive control of human papillomavirus infections and related diseases. *Vaccine* 2013;31 Suppl 8:11–131.
22. Van Doorslaer K. Evolution of the papillomaviridae. *Virology* 2013;445(1–2):11–20.
23. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell* 1990;63(6):1129–1136.
24. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. *Cell* 1993;75(3):495–505.
25. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. *Mol Cell Biol* 1993;13(2):775–784.
26. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. *Nature* 1996;380(6569):79–82.
27. White EA, Howley PM. Proteomic approaches to the study of papillomavirus-host interactions. *Virology* 2013;435(1):57–69.
28. Dyson N, Howley PM, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. *Science* 1989;243(4893):934–937.
29. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. *Virus Res* 2002;89(2):213–228.
30. Duensing S, Lee LY, Duensing A, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. *Proc Natl Acad Sci U S A* 2000;97(18):10002–10007.
31. DiMaio D, Pettit LM. The E5 proteins. *Virology* 2013;445(1–2):99–114.
32. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. *Nat Rev Microbiol* 2012;10(10):681–692.
33. Kemp TJ, Safaean M, Hildesheim A, et al. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(R). *Vaccine* 2012;31(1):165–170.
34. Haupt RM, Wheeler CM, Brown DR, et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. *Int J Cancer* 2011;129(11):2632–2642.
35. Kreuter A, Wieland U. Lack of efficacy in treating condyloma acuminata and preventing recurrences with the recombinant quadrivalent human papillomavirus vaccine in a case series of immunocompetent patients. *J Am Acad Dermatol* 2013;68(1):179–180.
36. Joura E, Team V-S, eds. Abstract SS 8–4: Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16- to 26-year-old women. Paper presented at: Eurogin 2013 International Multidisciplinary Congress; 2013; Florence, Italy.
37. Wang JW, Roden RB. L2, the minor capsid protein of papillomavirus. *Virology* 2013;445(1–2):175–186.
38. Ma B, Maraj B, Tran NP, et al. Emerging human papillomavirus vaccines. *Expert Opin Emerg Drugs* 2012;17(4):469–492.
39. Scudellari M. HPV: sex, cancer and a virus. *Nature* 2013;503(7476):330–332.
40. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine* 2012;30 Suppl 5:F34–54.
41. Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. *J Natl Cancer Inst* 2013;105(5):350–360.
42. Kempf W, Mertz KD, Hofbauer GF, et al. Skin cancer in organ transplant recipients. *Pathobiology* 2013;80(6):302–309.
43. Wallace NA, Gasior SL, Faber ZJ, et al. HPV 5 and 8 E6 expression reduces ATM protein levels and attenuates LINE-1 retrotransposition. *Virology* 2013;443(1):69–79.
44. White EA, Kramer RE, Tan MJ, et al. Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. *J Virol* 2012;86(24):13174–13186.
45. White EA, Sowa ME, Tan MJ, et al. Systematic identification of interactions between host cell proteins and E7 oncoproteins from diverse human papillomaviruses. *Proc Natl Acad Sci U S A* 2012;109(5):E260–267.
46. Caldeira S, Zehbe I, Accardi R, et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. *J Virol* 2003;77(3):2195–2206.
47. Arron ST, Ruby JG, Dybbro E, et al. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. *J Invest Dermatol* 2011;131(8):1745–1753.
48. Gross L. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. *Proc Soc Exp Biol Med* 1953;83(2):414–421.
49. Eddy BE, Stewart SE. Characteristics of the SE polyoma virus. *Am J Public Health Nations Health* 1959;49:1486–1492.
50. Sweet BH, Hilleman MR. The vacuolating virus, S.V. 40. *Proc Soc Exp Biol Med* 1960;105:420–427.
51. Eddy BE, Borman GS, Grubbs GE, et al. Identification of the oncogenic substance in rhesus monkey kidney cell culture as simian virus 40. *Virology* 1962;17:65–75.
52. Dang-Tan T, Mahmud SM, Puntoni R, et al. Polio vaccines, simian virus 40, and human cancer: the epidemiologic evidence for a causal association. *Oncogene* 2004;23(38):6535–6540.
53. Bouvard V, Baan RA, Grosse Y, et al. Carcinogenicity of malaria and of some polyomaviruses. *Lancet Oncol* 2012;13(4):339–340.
54. Gardner SD, Field AM, Coleman DV, et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. *Lancet*.1971;1(7712):1253–1257.
55. Padgett BL, Walker DL, Zur Rhein GM, et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. *Lancet* 1971;1(7712):1257–1260.
56. Das D, Wojno K, Imperiale MJ. BK virus as a cofactor in the etiology of prostate cancer in its early stages. *J Virol* 2008;82(6):2705–2714.
57. Akgul B, Pfister D, Knuchel R, et al. No evidence for a role of xenotropic murine leukaemia virus-related virus and BK virus in prostate cancer of German patients. *Med Microbiol Immunol* 2012;201(2):245–248.
58. Alexiev BA, Randhawa P, Vazquez Martul E, et al. BK virus-associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model. *Human Pathol* 2013;44(5):908–917.
59. Abend JR, Jiang M, Imperiale MJ. BK virus and human cancer: innocent until proven guilty. *Semin Cancer Biol* 2009;19(4):252–260.
60. Maginnis MS, Atwood WJ. JC virus: an oncogenic virus in animals and humans? *Semin Cancer Biol* 2009;19(4):261–269.
61. Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science* 2008;319(5866):1096–1100.
62. Hodgson NC. Merkel cell carcinoma: changing incidence trends. *J Surg Oncol* 2005;89(1):1–4.
63. Engels EA, Frisch M, Goedert JJ, et al. Merkel cell carcinoma and HIV infection. *Lancet* 2002;359(9305):497–498.

64. Zur Hausen A, Renmspiess D, Winnepenninckx V, et al. Early B-cell differentiation in Merkel cell carcinomas: clues to cellular ancestry. *Cancer Res* 2013;73(16):4982–4987.
65. Guastafierro A, Feng H, Thant M, et al. Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice. *J Virol Methods* 2013;187(1):6–14.
66. Schowalter RM, Pastrana DV, Pumphrey KA, et al. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. *Cell Host Microbe* 2010;7(6):509–515.
67. Faust H, Pastrana DV, Buck CB, et al. Antibodies to Merkel cell polyomavirus correlate to presence of viral DNA in the skin. *J Infect Dis* 2011;203(8):1096–1100.
68. Pastrana DV, Wieland U, Silling S, et al. Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer. *Med Microbiol Immunol* 2011;201(1):17–23.
69. Pastrana DV, Tolstov YL, Becker JC, et al. Quantitation of human seroreactivity to Merkel cell polyomavirus. *PLoS Pathog* 2009;5(9):e1000578.
70. Faust H, Andersson K, Ekstrom J, et al. Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma. *Int J Cancer* 2014;134(4):844–848.
71. Cheng J, Rozenblatt-Rosen O, Paulson KG, et al. Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. *J Virol* 2013;87(11):6118–6126.
72. Li J, Wang X, Diaz J, et al. Merkel cell polyomavirus large T antigen disrupts host genomic integrity and inhibits cellular proliferation. *J Virol* 2013;87(16):9173–9188.
73. Houben R, Shuda M, Weinkam R, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. *J Virol* 2010;84(14):7064–7072.
74. Houben R, Grimm J, Willmes C, et al. Merkel cell carcinoma and Merkel cell carcinoma polyomavirus: evidence for hit-and-run oncogenesis. *J Invest Dermatol* 2012;132(1):254–256.
75. Shuda M, Chang Y, Moore PS. Merkel cell polyomavirus positive Merkel cell carcinoma requires viral small T antigen for cell proliferation. *J Invest Dermatol* 2013 [Epub ahead of print].
76. Paulson KG, Iyer JG, Tegeeder AR, et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. *J Clin Oncol* 2011;29(12):1539–1546.
77. Arora R, Shuda M, Guastafierro A, et al. Survivin is a therapeutic target in Merkel cell carcinoma. *Sci Transl Med* 2012;4(133):133ra56.
78. Dresang LR, Guastafierro A, Arora R, et al. Response of merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor. *PLoS One* 2013;8(11):e80543.
79. Shuda M, Kwun HJ, Feng H, et al. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. *J Clin Invest* 2011;121(9):3623–3634.
80. Howard RA, Dores GM, Curtis RE, et al. Merkel cell carcinoma and multiple primary cancers. *Cancer Epidemiol Biomarkers Prev* 2006;15(8):1545–1549.
81. Pantulu ND, Pallasch CP, Kurz AK, et al. Detection of a novel truncating Merkel cell polyomavirus large T antigen deletion in chronic lymphocytic leukemia cells. *Blood* 2010;116(24):5280–5284.
82. Tolstov YL, Arora R, Scudiere SC, et al. Lack of evidence for direct involvement of Merkel cell polyomavirus (MCV) in chronic lymphocytic leukemia (CLL). *Blood* 2010;115(23):4973–4974.
83. Cimino PJ, Jr., Bahler DW, Duncavage EJ. Detection of Merkel cell polyomavirus in chronic lymphocytic leukemia T-cells. *Exp Mol Pathol* 2013;94(1):40–44.
84. Burkitt D. A sarcoma involving the jaws in African children. *Br J Surg* 1958;46(197):218–223.
85. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. *Lancet* 1964;1(7335):702–703.
86. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. *Proc Natl Acad Sci U S A* 1968;59(1):94–101.
87. Longnecker RM, Kieff E, Cohen JL. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. *Fields Virology*. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
88. Cesarman E. Gammaherpesviruses and lymphoproliferative disorders. *Annu Rev Pathol* 2014;9:349–372.
89. Shannon-Lowe C, Rowe M. Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. *PLoS Pathog* 2011;7(5):e1001338.
90. Faulkner GC, Burrows SR, Khanna R, et al. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. *J Virol* 1999;73(2):1555–1564.
91. Hjalgrim H, Smedby KE, Rostgaard K, et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. *Cancer Res* 2007;67(5):2382–2388.
92. Barton ES, White DW, Cathelyn JS, et al. Herpesvirus latency confers symbiotic protection from bacterial infection. *Nature* 2007;447(7142):326–329.
93. Giulino-Roth L, Cesarman E. Molecular biology of Burkitt lymphoma. In: Robertson E, ed. *Burkitt's Lymphoma*. New York, NY: Springer; 2013: 211–226.
94. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiol Biomarkers Prev* 2006;15(10):1765–1777.
95. Murukesan V, Mukherjee S. Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens. *Drugs* 2012;72(12):1631–1643.
96. Cohen JL, Mocarski ES, Raab-Traub N, et al. The need and challenges for development of an Epstein-Barr virus vaccine. *Vaccine* 2013;31(Suppl 2): B194–196.
97. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. *Blood* 2006;107(8):3053–3057.
98. Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. *Ann Oncol* 2011;22(8):1859–1864.
99. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. *Archiv für Dermatologie und Syphilis* 1872;4(2):265–273.
100. Antman K, Chang Y. Kaposi's sarcoma. *N Engl J Med* 2000;342(14):1027–1038.
101. Beral V, Peterman TA, Berkelman RL, et al. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? *Lancet* 1990;335(8682):123–128.
102. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 1994;266(5192):1865–1869.
103. Damania BA, Cesarman E. Kaposi's sarcoma-associated herpesvirus. In: Knipe DM, Howley PM, eds. *Fields Virology*. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
104. Cook-Mozaffari P, Newton R, Beral V, et al. The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. *Br J Cancer* 1998;78(11):1521–1528.
105. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. *N Engl J Med* 1999;340(14):1063–1070.
106. Krown SE, Dittmer DP, Cesarman E. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. *J Infect Dis* 2011;203(8):1082–1086.
107. Sakakibara S, Tosato C. Regulation of angiogenesis in malignancies associated with Epstein-Barr virus and Kaposi's sarcoma-associated herpes virus. *Future Microbiol* 2009;4(7):903–917.
108. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castlemans disease. *Blood* 1995;86(4):1276–1280.
109. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. *Blood* 2013;122(26):4189–4198.
110. Simonelli C, Spina M, Cinelli R, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. *J Clin Oncol* 2003;21(21):3948–3954.
111. Coffin JM, Hughes SH, Varmus HE, eds. The interactions of retroviruses and their hosts. *Retroviruses*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1997.
112. Gallo RC. History of the discovery of the first human retroviruses: HTLV-1 and HTLV-2. *Oncogene* 2005;24:5926–5930.
113. Smit AF, Riggs AD. Tiggers and DNA transposon fossils in the human genome. *Proc Natl Acad Sci U S A* 1996;93:1443–1448.
114. Delviks-Frankenberry K, Paprotka T, Cingöz O, et al. Generation of multiple replication-competent retroviruses through recombination between PreX-MRV-1 and PreXMRV-2. *J Virol* 2013;87:11525–11537.
115. Mason AL, Zhang G. Linking human beta retrovirus infection with primary biliary cirrhosis. *Gastroenterol Clin Biol* 2010;34:359–366.
116. Hacein-Bey-Abina S, VonKalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* 2003;302:415–419.
117. Matsuoka M, Jeang K-T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. *Nat Rev Cancer* 2007;7:270–280.
118. Poiesz BJ, Ruscetti FW, Mier JW, et al. T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. *Proc Natl Acad Sci U S A* 1980;77:6815–6819.
119. Kalyanaraman VS, Samgadharan MG, Robert-Guroff M, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. *Science* 1982;218:571–573.
120. Wolfe ND, Heneine W, Carr JK, et al. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters. *Proc Natl Acad Sci U S A* 2005;102:7994–7999.
121. Goncalves DU, Prioretti FA, Ribas JGR, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. *Clin Microbiol Rev* 2010;23:577–589.
122. Hino S, Sugiyama H, Doi H, et al. Breaking the cycle of HTLV-1 transmission via carrier mothers' milk. *Lancet Oncol* 1987;2:158–159.
123. Kannian P, Green PL. Human T lymphotropic virus type 1 (HTLV-1): molecular biology and oncogenesis. *Viruses* 2010;2:2037–2077.
124. Hill SA, Lloyd PA, McDonald S, et al. Susceptibility of human T cell leukemia virus type 1 to nucleoside reverse transcriptase inhibitors. *J Infect Dis* 2003;188:424–427.
125. Seegulam ME, Ratner L. Integrase inhibitors effective against human T-cell leukemia virus type 1. *Antimicrob Agents Chemother* 2011;55:2011–2017.

126. Derse D, Crise B, Li Y, et al. Human T-cell leukemia virus type I integration target sites in the human genome: comparison with those of other retroviruses. *J Virol* 2007;81:6731–6741.
127. Jones KS, Lambert S, Bouttier M, et al. Molecular aspects of HTLV-1 entry: functional domains of the HTLV-1 surface subunit (SU) and their relationships to the entry receptors. *Viruses* 2011;3:794–810.
128. Matsuoka M, Green PL. The HBZ gene, a key player in HTLV-1 pathogenesis. *Retrovirology* 2009;6:71.
129. Grossman WJ, Kimata JT, Wong FH, et al. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. *Proc Natl Acad Sci U S A* 1995;92:1057–1061.
130. El Hajj H, El-Sabban M, Hasegawa H, et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. *J Exp Med* 2010;207:2785–2792.
131. Villaudy J, Wencker M, Gadot N, et al. HTLV-1 propels thymic human T cell development in “human immune system” Rag2-/-IL-2Rgamma-/- mice. *PLoS Pathog* 2011;7:e1002231.
132. Costa EAS, Magri MC, Caterino-de-Arujo A. The best algorithm to confirm the diagnosis of HTLV-1 and HTLV-2 in at-risk individuals from Sao Paulo, Brazil. *J Virol Methods* 2011;173:280–286.
133. Barros N, Woll F, Watanabe L, et al. Are increased Foxp3+ regulatory T cells responsible for immunosuppression during HTLV-1 infection? Case reports and review of the literature. *BMJ Case Rep* 2012;bc2012006574.
134. Cook LB, Rowan AG, Melamed A, et al. HTLV-1-infected T cells contain a single integrated provirus in natural infection. *Blood* 2012;120:3488–3490.
135. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: a report from the Lymphoma Study Group. *Br J Hematol* 1991;79:426–437.
136. Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. *Blood* 2010;115:4337–4343.
137. Bazarbachi A, Plumelle Y, Ramos JC, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. *J Clin Oncol* 2010;28:4177–4183.
138. Katsuya H, Yamanka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. *J Clin Oncol* 2012;30:1635–1640.
139. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. *J Clin Oncol* 2009;27:453–459.
140. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF supported combination chemotherapy, LSG15, for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study 9303. *Br J Hematol* 2001;113:375–382.
141. Ratner L, Harrington W, Feng X, et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. AIDS Malignancy Consortium. *PLoS One* 2009;4:e4420.
142. Tatsuhiro J, Ishida T, Takemoto S, et al., eds. Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSC15) versus mLSC15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL). Paper presented at: 2013 ASCO Annual Meeting; 2013; Chicago, IL.
143. Bazarbachi A, Suarez F, Fields P, et al. How I treat adult T-cell leukemia/lymphoma. *Blood* 2011;118:1736–1745.
144. Utsonomiya A, Miyazaki Y, Takasuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2001;27:15–20.
145. Blumberg BS. The discovery of the hepatitis B virus and the intervention of the vaccine: a scientific memoir. *J Gastroenterol Hepatol* 2002;17(Supplement 4):S502–S503.
146. Houghton M. Discovery of the hepatitis C virus. *Liver Int* 2009;29(Supplement 1):82–88.
147. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. *Nat Rev Cancer* 2013;13:123–135.
148. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. *Lancet* 2012;380:1840–1850.
149. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. *J Clin Oncol* 2009;27:1485–1491.
150. Shiffman ML, ed. *Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future*. New York: Springer Verlag; 2011.
151. Nicot F, Nassim K, Lionel R, et al. Occult hepatitis C virus infection: Where are we now? *Liver Biopsy in Modern Med* 2004;307–334.
152. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 2001;34:809–816.
153. Wilkins T, Malcom JK, Raina D, et al. Hepatitis C: diagnosis and treatment. *Am Fam Physician* 2010;81:1351–1357.
154. Fallot G, Neuveut C, Buendia M-A. Diverse roles of hepatitis B virus in liver cancer. *Curr Opin Virol* 2012;2:467–473.
155. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. *N Engl J Med* 2004;350:1118–1129.
156. Tujios SR, Lee WM. Update in the management of chronic hepatitis B. *Curr Opin Gastroenterol* 2013;29:250–256.
157. Seto W-K, Fung J, Yuen M-F, et al. Future prevention and treatment of chronic hepatitis B infection. *J Clin Gastroenterol* 2012;46:725–734.
158. Wang WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. *Leuk Lymphoma* 2003;44:1113–1120.
159. Fernandez-Garcia M-D, Mazzon M, Jacobs M, et al. Pathogenesis of flavivirus infections: using and abusing the host cell. *Cell Host Microbe* 2009;3:318–328.
160. Moradpour D, Penin F, Rice CM. Replication of hepatitis c virus. *Nat Rev Microbiol* 2007;5:453–463.
161. Liang TJ, Ghany MC. Current and future therapies for hepatitis C virus infection. *N Engl J Med* 2013;368:1907–1917.
162. Kimer N, Dahl EK, Gluud LL, et al. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. *BMJ Open* 2012;2:e001313.
163. Fujimoto A, Totoki Y, Abe T, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. *Nat Genet* 2012;44:760–764.
164. Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. *Nat Genet* 2012;44:765–769.
165. Devi U, Locarnini S. Hepatitis B antivirals and resistance. *Curr Opin Virol* 2013;3:495–500.
166. Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. *Semin Immunopathol* 2013;35:111–120.
167. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011;53:1020–1022.
168. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996;334:693–699.
169. Mino M, Lauwers GY. Pathologic spectrum and prognostic significance of underlying liver disease in hepatocellular carcinoma. *Surg Oncol Clin N Am* 2003;12:13–24.
170. Burton JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. *Clin Liver Dis* 2013;17:73–91.
171. Beckebaum S, Kabar I, Cicinnati VR. Hepatitis B and C in liver transplantation: new strategies to combat the enemies. *Rev Med Virol* 2012;23:172–193.
172. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. *Nat Rev Clin Oncol* 2012;9:156–166.
173. Huang Y-H, Hsiao L-T, Hong Y-C, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis. *J Clin Oncol* 2013;31:2765–2772.
174. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. *J Clin Oncol* 2010;28:3199–3202.
175. Forghieri F, Luppi M, Barozzi P, et al. Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. *Clin Dev Immunol* 2012;2012:807351.